NEWPORT, Ky., June 12 /PRNewswire/ -- Xanodyne Pharmaceuticals, Inc. is pleased to announce the appointment of Mr. Vaughn M. Kailian to the Company's Board of Directors. Mr. Kailian is currently Managing Director of MPM Capital and brings extensive commercial and general management experience to Xanodyne's Board. Mr. Kailian joined MPM's Boston office in 2005 and brought to MPM unparalleled success in stewardship of commercial biotech and pharmaceutical companies.
Mr. Kailian's current Board assignments include; Cephalon, Inc. and NicOx, S.A. In addition, Mr. Kailian is the current Chairman of Elixir Pharmaceuticals, Inc., Cerimon Pharmaceuticals, Inc. and Valeritas, Inc. Mr. Kailian is also a member of the Board of BIO (the Biotechnology Industry Organization), BIO Ventures for Global Health and the New England Healthcare Institute.
Mr. Kailian has numerous accomplishments in the pharmaceutical industry including serving as CEO of COR Therapeutics, Inc. (1990-2002) where he took the company public in 1991, raised almost $1 billion in public market capital, and led the $2 billion merger with Millennium Pharmaceuticals, Inc. in 2002. Mr. Kailian served as the vice chair of the Board of Directors of Millennium Pharmaceuticals, Inc. where he was also the head of the Millennium commercial organization (2002-2004).
Earlier in his career, Mr. Kailian held various international and U.S. general management, marketing and sales positions at Marion Merrell Dow, Inc. and its predecessor companies including president and general manager, Merrell Dow USA and corporate vice president of Global Commercial Development, Marion Merrell Dow, Inc.
Xanodyne Pharmaceuticals, Inc., which commenced operations in 2001, is an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management. Xanodyne markets a portfolio of revenue generating products consisting of FDA approved pharmaceuticals and a line of prenatal vitamins. Additionally, Xanodyne is advancing a late stage pipeline of product candidates targeted at significant potential markets in Xanodyne's focus areas.
|SOURCE Xanodyne Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved